Illumina General

Overview

© 2020 Illumina, Inc. All rights reserved.

What Can We Do by Knowing Your Genome?

Guide selection of Suggest Provide family Help inform proactive

drug choices predispositions planning insight health management
and symptoms

2
 Accelerating Pace of Genomic Applications

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

For Research Use Only. Not for use in diagnostic procedures. 3

Our Mission

Unlocking the Power of the Genome

to Improve Human Health

4
Who We Are

As a global leader in DNA sequencing and microarray-based solutions, we are dedicated

to improving human health by unlocking the power of the genome. Our technology is responsible
for generating more than 90% of the world’s sequencing data.*

$3.3 billion (2018) >7,800 Francis deSouza San Diego, CA, USA 1998
Annual revenue Number of employees President & CEO Headquarters Year founded

*Data calculations on file. Illumina, Inc. 2017

5
Where We Operate
Évry Cambridge Eindhoven Berlin Seoul Tokyo / Osaka
United States Netherlands
• San Diego • Eindhoven
(Headquarters)
• Foster City
• Hayward China
• Madison • Beijing
• Shanghai

Brazil
• São Paulo Japan
• Tokyo
• Osaka
United Kingdom
• Cambridge
Singapore

France Australia
• Évry • Melbourne

Germany South Korea

San Diego (Headquarters) / • Berlin • Seoul
Foster City / Hayward / Madison São Paulo Beijing / Shanghai Singapore Melbourne

6
Making Breakthroughs Possible
Cost of Sequencing, Per Human Whole Genome
Illumina has developed
one of the world’s most 2001 $100 million1
comprehensive genomics
portfolio of integrated
systems, consumables,
and analysis tools. 2019 $1,0002
With each technological
breakthrough, we help
scientists better understand
genetic variation at all levels Since 2001, the cost of DNA sequencing has dropped more than 100,000x
of complexity. from $100 million per human genome to less than $1,000 today. Discoveries
that were unimaginable a few years ago are now becoming routine.

1. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: www.genome.gov/sequencingcosts
2. NovaSeq™ 6000 Sequencing System. Data on file.

7
A Recognized Leader

Top CEOs 50 Smartest Companies 10 Most Innovative World’s Most Innovative

Glassdoor (#44) MIT Technology Review Biotech Companies Companies List
2018 2014 (#1), 2015 (#3),
Fast Company Forbes 2014 (#36)
2016 (#3), 2017 (#22)
2016, 2017 Forbes 2015 (#35)
Forbes 2016 (#24)
Forbes 2017 (#18)
Forbes 2018 (#20)

10 Breakthrough Best Places to Work Fastest-Growing Tech

Technologies 2013 2018 Forbes America's Best Midsize Companies
MIT Technology Review Employers (#142 of 500)
Fortune 2016
2013 2019 Glassdoor Employees’ Choice Fortune Future 50 2018 (#36)
Best Place to Work (#33)

8
Our Vision for Genomics: Genomics for Good

The iHope Program

Created by Illumina, demonstrates the potential
of clinical whole-genome sequencing, its
benefits and immediate impact for patients living
without a diagnosis.

The iHope Program has helped several families

uncover underlying genetic disease, allowing
them to establish an individualized path toward
disease management and treatment.

9
>13,000 Active Instruments Globally

~100 Pb
Sequence Data
in 2018

~600 ~2,100 ~3,000 ~6,700 ~900 ~350

NovaSeq™ 6000 HiSeq™ NextSeq™ MiSeq™ MiniSeq™ iSeq™100

High Throughput Mid Throughput Benchtop

™

For Research Use Only. Not for use in diagnostic procedures. 10

Illumina Instruments
Sequencing Systems
NovaSeq™ 6000
High-throughput sequencing
for virtually any species, application,
or scale of sequencing project,
including genomes, exome,
and transcriptomes.
MiniSeq™
Benchtop sequencer for
targeted DNA and targeted
RNA sequencing.
Array Scanners
iScan™ System
Genotyping, CNV analysis,
DNA methylation, and gene
expression profiling.
NextSeq™ 1000/2000
Emerging and mid-throughput
sequencer supports a broad range
of applications and methods,
including exome sequencing, target
enrichment, single-cell profiling, and
transcriptome sequencing.
iSeq™ 100
Benchtop sequencer for
targeted gene sequencing, direct
amplicon sequencing, and small-
genome sequencing.
For Research Use Only. Not for use in diagnostic procedures.
NextSeq™ 550
Benchtop sequencer for genome
sequencing, exome sequencing,
transcriptome sequencing and
cytogenomic and methylation
array scanning.
NextSeq™ 550Dx*
Benchtop FDA-regulated sequencer
for comprehensive cancer testing
and NIPT, as well as clinical
research applications, from targeted
panels to exomes; cleared or
approved in > 20 countries.
*For In Vitro Diagnostic Use.
MiSeq™
Benchtop sequencer for targeted
and small-genome sequencing.
MiSeq™ Dx*
Benchtop IVD sequencer for
targeted tumor profiling and genetic
disease testing, as well as clinical
research applications including
amplicon sequencing; cleared or
approved in >20 countries.
*For In Vitro Diagnostic Use.
11
Leveraging Our Technology
Integrated workflows from prepared sample to answer

Flexible workflow solutions enable markets

Simplified Custom Flexible, economical Integrated

library prep content sequencing analysis

For Research Use Only. Not for use in diagnostic procedures. 12

Who We Serve

Reproductive Genetic Molecular and

Oncology Microbiology Agriculture
Health Disease Cell Biology

Universities and Consumer

Pharmaceutical Genome Biotechnology Government
Academic Hospitals Genetics
Companies Centers Companies Agencies
Research Centers Companies

For Research Use Only. Not for use in diagnostic procedures. 13

The Latest in Population-Scale Sequencing
Enabled by Illumina technologies’ speed and throughput

White House Initiative for China’s Precision

Precision Medicine Medicine Initiative
$215M investment; $10B over 15 years;
Calls for new era of precision medicine 2 million people

France Investment in
Genomics England Genome Sequencing
Sequence 100,000 genomes over $745M to build 235,000 genomes-
4 years per-year sequencing operation

14
Thank you!

© 2020 Illumina, Inc. All rights reserved.